Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 18, 2007New U.S. shelf life is longer than any competing drug-eluting stent product
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of...
-
Jan 17, 2007Court Orders Injunction and Damages
Boston Scientific Corporation (NYSE: BSX) announced today that it and Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI; TSX: ANP) won a patent...
-
Jan 16, 2007
Boston Scientific Corporation (NYSE: BSX) commented on a decision today by the U.K. Court of Appeal that affirmed an earlier ruling by a lower...
-
Jan 12, 2007Lower rates of re-intervention and major adverse events reported for the TAXUS Stent in study of diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of an independent study demonstrating that Boston Scientific's TAXUS®...
-
Jan 11, 2007Boston Scientific only company to offer two distinct drug-eluting stent platforms
Boston Scientific Corporation (NYSE:BSX) today announced the international launch and first implantation of the PROMUS(TM) Everolimus-Eluting...
-
Jan 10, 2007
Boston Scientific Corporation (NYSE: BSX) today announced preliminary, unaudited net sales for its fourth quarter and full year ended December 31,...
-
Jan 8, 2007Plan to increase innovation, productivity and competitiveness
Boston Scientific Corporation (NYSE: BSX) today announced a plan to reallocate its cardiac rhythm management (CRM) research and development...
-
Jan 4, 2007Acquisition demonstrates Company's commitment to leadership in treating carotid artery disease
Boston Scientific Corporation (NYSE: BSX) today announced it has acquired EndoTex Interventional Systems, Inc. The acquisition follows the Food and...
-
Jan 3, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the JP Morgan Health Care Conference, which is being held January 8 - 11 in...
-
Jan 2, 2007Trial highlights the importance of appropriate pacing for patients at risk of sudden cardiac death
Boston Scientific Corporation (NYSE: BSX) today announced that results of the largest implantable cardioverter defibrillator (ICD) study to date,...
-
Dec 15, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling certain lots of the Mach 1® Guide Catheter in the...
-
Dec 14, 2006Device now cleared for use in both carotid arteries and saphenous vein grafts
Boston Scientific Corporation (NYSE: BSX) today announced it has received clearance from the U.S. Food and Drug Administration (FDA) to market its...
-
Dec 7, 2006
Boston Scientific Corporation (NYSE: BSX) today presented data on its 7,000- patient ARRIVE I and II registries of real-world...
-
Dec 7, 2006
Boston Scientific Corporation (NYSE: BSX) today presented data on its long- term randomized clinical trials to a special U.S....
-
Nov 21, 2006
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held November 29...
-
Nov 15, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Brenda Becker will be appointed Senior Vice President of Global Government Affairs....
-
Nov 14, 2006Lower re-intervention rates for the TAXUS Stent in diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed a presentation by Joost Daemen, M.D., and Patrick Serruys, M.D., entitled...
-
Nov 9, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's LATITUDE® 2.0...
-
Nov 6, 2006
At a meeting with analysts today, Boston Scientific Corporation (NYSE: BSX) provided its financial outlook for 2007. Sales goals for 2007 range...
-
Nov 6, 2006
Boston Scientific Corporation (NYSE: BSX) today presented a four-year update of its key randomized, controlled clinical trials (TAXUS II, IV, V and...
-
Nov 6, 2006Technology serves as second-generation platform for Company's market-leading TAXUS® paclitaxel-eluting coronary stent system
Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare...
-
Nov 3, 2006Company to acquire EndoTex
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the NexStent® Carotid Stent...
-
Nov 3, 2006Innovative Technology Makes Precision™ Spinal Cord Stimulator Accessible to More Patients
Boston Scientific Corporation (NYSE: BSX) today announced that it has received the European CE Mark for its new Artisan™ 2x8 Surgical Lead for use...
-
Nov 2, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Daniel J. Brennan has been appointed to the position of Vice President Investor...
-
Nov 2, 2006
Boston Scientific Corporation (NYSE: BSX) will simultaneously webcast the analyst meeting it is hosting on Monday, November 6. The meeting is...